Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chugai Pharmaceutical Co ( (JP:4519) ) has shared an update.
F. Hoffmann-La Roche, the Swiss healthcare group and parent of Chugai Pharmaceutical, has reported its sales for the first quarter of 2026, covering the period from January 1 to March 31. Chugai’s financial performance for the same period is consolidated into these Roche Group results, meaning investors must refer to Roche’s published materials for detailed figures and analysis of Chugai’s contribution.
The announcement underscores Chugai’s integration within Roche’s global operations, as its quarterly results are not disclosed separately at this stage but through Roche’s group reporting. This structure highlights Chugai’s strategic role within the broader Roche ecosystem and signals that key performance indicators relevant to Chugai shareholders and stakeholders will be reflected in Roche’s investor updates.
The most recent analyst rating on (JP:4519) stock is a Buy with a Yen9800.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange. Focused on prescription medicines and innovative therapies, it operates as part of the Roche Group, with Roche Holding Ltd. owning a controlling stake in Chugai’s issued shares and voting rights.
Average Trading Volume: 2,497,336
Technical Sentiment Signal: Buy
Current Market Cap: Yen14295.2B
Find detailed analytics on 4519 stock on TipRanks’ Stock Analysis page.